Ono Deplores Regulator’s Decision on Opdivo Spillover Re-Pricing

Ono Pharmaceutical is immensely dissatisfied over the market expansion re-pricing of its PD-1 inhibitor Opdivo (nivolumab) under the so-called “spillover” rule in the FY2024 price reform, the company told Jiho on January 17. The comment came after the Central Social...read more